

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Patent Claims

1. (Currently Amended) A transdermal therapeutic system (~~TTS~~) for continuous administration of pramipexol[[,]] comprising a backing layer and at least one active ingredient-containing polymer layer which comprises the active ingredient pramipexol, wherein the active ingredient-containing polymer layer comprises at least one pressure-sensitive adhesive polymer selected from the group of silicones (~~polydimethylsiloxanes~~), ~~of~~ polyisobutylenes, ~~of~~ polybutenes, ~~of~~ styrene-isoprene-styrene block copolymers in combination with resins, and of carboxyl group-free polyacrylates, where the active ingredient pramipexol is present therein in a proportion of between 10 and 40 % by weight.
2. (Currently Amended) The TTS transdermal therapeutic system as claimed in claim 1, which comprises a further pressure-sensitive adhesive layer, an additional membrane which controls the rate of release of pramipexol, an additional active ingredient-containing layer or an additional supporting layer.
3. (Currently Amended) The TTS transdermal therapeutic system as claimed in claim 1 ~~or~~ 2, wherein the pressure-sensitive adhesive polymer is a carboxyl group-free polyacrylate which can be prepared by polymerization of a monomer mixture of at least one acrylic ester or methacrylic ester.

4. (Currently Amended) The TTS transdermal therapeutic system as claimed in claim 3, wherein the monomer mixture comprises at least one acrylic ester or methacrylic ester with linear, branched or cyclic aliphatic C₁-C₁₂ substituents without other functional groups.
5. (Currently Amended) The TTS transdermal therapeutic system as claimed in claim 3 or 4, wherein the monomer mixture additionally comprises at least one hydroxyl group-containing acrylic ester or one hydroxyl group-containing methacrylic ester in a proportion by weight of less than 10 %.
6. (Currently Amended) The TTS transdermal therapeutic system as claimed in ~~one or more~~ of claim[[s]] 3 ~~to 5~~, wherein the monomer mixture additionally comprises vinyl acetate in a proportion by weight of less than 50 %[[,]] ~~preferably less than 25 % and particularly preferably between 0 and 5 %.~~
7. (Currently Amended) The TTS transdermal therapeutic system as claimed in ~~one or more~~ of the preceding claims claim 1, wherein the active ingredient pramipexol is present in the active ingredient-containing polymer layer in dissolved, emulsified and/or dispersed form.
8. (Currently Amended) The TTS transdermal therapeutic system as claimed in ~~one or more~~ of the preceding claims claim 1, wherein the active ingredient pramipexol is present as S-(-) enantiomer, R-(+) enantiomer or racemic mixture of these two enantiomers in the active ingredient-containing polymer layer.
9. (Currently Amended) The TTS transdermal therapeutic system as claimed in ~~one or more~~ of the preceding claims claim 1, wherein the active ingredient pramipexol is present as a free base, as hydrate, solvate and/or pharmaceutically acceptable salt in the active ingredient-containing polymer layer.

10. (Currently Amended) The TTS transdermal therapeutic system as claimed in ~~one or more~~ ~~of the preceding claims~~ claim 1, wherein the active ingredient pramipexol is present as S-(-) enantiomer in the form of ~~the~~ a free base in the active ingredient-containing polymer layer.
11. (Currently Amended) The TTS transdermal therapeutic system as claimed in ~~one or more~~ ~~of the preceding claims~~ claim 1, ~~which is able to deliver~~ wherein said transdermal therapeutic system delivers the active ingredient pramipexol continuously to a patient's skin over a period of from 4 to 7 days.
12. (Currently Amended) The TTS transdermal therapeutic system as claimed in ~~one or more~~ ~~of the preceding claims~~ claim 1, which is able to release the active ingredient pramipexol with a flux rate greater than $5 \mu\text{g}/\text{cm}^2 \text{ h}$ over the period between 24 hours after administration to 168 h after administration.
13. (Currently Amended) The TTS transdermal therapeutic system as claimed in ~~one or more~~ ~~of the preceding claims~~ claim 1, ~~which is able to release~~ said transdermal therapeutic system releasing the active ingredient pramipexol with a flux rate greater than $5 \mu\text{g}/\text{cm}^2 \text{ h}$ over the period between 24 hours after administration to 72 h after administration.
14. (Currently Amended) The TTS transdermal therapeutic system as claimed in ~~one or more~~ ~~of the preceding claims~~ claim 1, wherein the active ingredient pramipexol is present therein in a proportion of between 10 and 25 % by weight.
15. (Currently Amended) The TTS transdermal therapeutic system as claimed in ~~one or more~~ ~~of the preceding claims~~ claim 1, wherein the daily delivery rate of pramipexol is between 0.1-10 mg[[,]] ~~preferably between 0.5-4.5 mg.~~

16. (New) The transdermal therapeutic system as claimed claim 6, wherein said vinyl acetate is present in a proportion of less than 25% by weight.
17. (New) The transdermal therapeutic system as claimed claim 15, wherein the daily delivery rate of pramipexol is between 0.5 to 4.5 mg.